908 Devices Q2 revenue beats on increased VipIR sales

908 Devices

11/08/2026 12:16

Overview
U.S. handheld chemical analysis tool maker's Q2 revenue grew 23%, beating analyst expectations
Net loss for Q2 widened, missing analyst estimates
Company raised low end of 2026 revenue outlook, now expects 21% to 25% growth

Outlook
908 Devices raises 2026 revenue outlook to $68 mln-$70 mln, up from $67 mln-$70 mln
Company expects 2026 revenue growth of 21% to 25% year-over-year
Company cites robust pipeline and recent orders supporting second-half revenue outlook

Result Drivers
VIPIR PRODUCT SALES - Co said Q2 revenue growth was driven by increased sales of VipIR chemical identification devices
U.S. AGENCY DEMAND - Co said momentum with U.S. state and local customers remained strong, representing more than half of revenue
CHANNEL MIX SHIFT - Co attributed improved adjusted gross margin to higher product revenues and a shift in channel mix

Company press release: ID:nBw44tq7na

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$16.10 mln
$15.37 mln (5 Analysts)
Q2 Loss Per Share
 
$0.32
 
Q2 Net Loss
Miss
$11.90 mln
$6.32 mln (3 Analysts)
Q2 Gross Profit
 
$8.30 mln
 
Q2 Operating Expenses
 
$21.20 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for 908 Devices Inc. is $11.00, about 25% above its August 10 closing price of $8.80

Reuters Recommended Reads
Aug 10 - Mesa Labs Q1 revenue rises as calibration, biopharma units grow
Aug 10 - Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost
Aug 10 - inTEST slightly beats Q2 revenue estimates on auto/EV growth, keeps FY revenue  view

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)